Search Results - "Stein‐Gold, L."

Itch: an under‐recognized problem in psoriasis by Elewski, B., Alexis, A.F., Lebwohl, M., Stein Gold, L., Pariser, D., Del Rosso, J., Yosipovitch, G.

“…Psoriasis has historically been considered a nonpruritic dermatosis, in contrast with atopic dermatitis. Thus, itch has often been underappreciated and…”
Get full text

Efficacy and safety of fixed‐dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis by Stein Gold, L., Paul, C., Romiti, R.

“…The fixed‐dose combination calcipotriol (Cal; 50 µg/g) plus betamethasone dipropionate (BD; 0.5 mg/g) ointment and gel formulations have well‐established…”
Get full text

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study by Paul, C., Stein Gold, L., Cambazard, F., Kalb, R.E., Lowson, D., Bang, B., Griffiths, C.E.M.

“…Background Fixed combination calcipotriol 50 μg/g (Cal) plus betamethasone 0.5 mg/g (BD) foam has been developed as a new treatment option for patients with…”
Get full text

Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study by Van Voorhees, A.S., Stein Gold, L., Lebwohl, M., Strober, B., Sofen, H., Papp, K., Bagel, J., Zhang, Z., Paris, M., Wang, Y.

Get full text

Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study by Eichenfield, L.F., Del Rosso, J.Q., Tan, J.K.L., Hebert, A.A., Webster, G.F., Harper, J., Baldwin, H.E., Kircik, L.H., Stein‐Gold, L., Kaoukhov, A., Alvandi, N.

“…Summary Background Once‐daily topical oxymetazoline cream 1·0% significantly reduced persistent facial erythema of rosacea in trials requiring live, static…”
Get full text

Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam by Jalili, A., Lebwohl, M., Stein Gold, L., Andersen, S.B., Jensen, K.L., Pink, A.E., Segaert, S., Berg, P., Calzavara‐Pinton, P.G., Cueva Dobao, P., Thaçi, D.

“…Background Itch is common in psoriasis, adversely affecting health‐related quality of life (HRQoL) and sleep. Objective We evaluated the efficacy of topical…”
Get full text

Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study by Lebwohl, M.G., Stein Gold, L., Papp, K., Han, G., Pariser, D.M., Lin, T., Harris, S., Jacobson, A.

“…Background The topical corticosteroid halobetasol propionate (HP) and the retinoid tazarotene (TAZ) are effective in psoriasis treatment. To mitigate adverse…”
Get full text

Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies by Zane, LT, Chanda, Jarnagin, Nelson, DB, Spelman, Gold, LF Stein

“…Atopic dermatitis (AD), a chronic, relapsing, inflammatory skin disease that is characterized by intense pruritus and eczematous lesions with up to 90% of…”
Get full text

O064 Long-term safety of crisaborole topical ointment, 2%, in atopic dermatitis by Eichenfield, L, Call, R, Forsha, D, Fowler, J, Hebert, A, Spellman, M, Stein Gold, L, Van Syoc, M, Zane, L, Tschen, E

Get full text

CO81 Efficacy and Safety of Clascoterone Cream 1% in Patients with Acne vulgaris across Subgroups Defined By Demographic Characteristics by Eichenfield, L.F., Hebert, A.A., Stein Gold, L., Cartwright, M., Moro, L., Han, J., Squittieri, N., Mazzetti, A.

Get full text

CO125 Efficacy of Clascoterone Cream 1% for up to 12 Months in Patients ≥9 Years of Age with Acne vulgaris: Results from a Long-Term Extension Study by Eichenfield, L.F., Hebert, A.A., Stein Gold, L., Cartwright, M., Moro, L., Han, J., Squittieri, N., Mazzetti, A.

Get full text

CO45 Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults with Chronic Plaque Psoriasis from a 52-Week, Phase 2 Open-Label Safety Trial by Lebwohl, M., Stein Gold, L., Gooderham, M., Papp, K.A., Ferris, L.K., Adam, D.N., Hong, H.C.H., Kircik, L.H., Zirwas, M., Burnett, P., Higham, R., Krupa, D., Berk, D.R.

Get full text

LB756 Patient-reported outcomes for sarecycline effectiveness in Acne Vulgaris in real-world settings: PROSES study protocol by Graber, E., Baldwin, H., Harper, J., Alexis, A., Gold, L. Stein, Hebert, A., Fried, R., Rieder, E., Kircik, L., Del Rosso, J., Kasujee, I., Grada, A.

Get full text

Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study by Strober, Bruce, Bagel, Jerry, Lebwohl, Mark, Stein Gold, Linda, Jackson, J Mark, Chen, Rongdean, Goncalves, Joana, Levi, Eugenia, Callis Duffin, Kristina

“…INTRODUCTION: Many options are available for patients with moderate to severe plaque psoriasis. Patients with moderate disease, however, are often undertreated…”
Get more information

Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination by Jalili, Ahmad, Bewley, Anthony, Sticherling, Michael, Stein Gold, Linda

“…Psoriasis is a well-known chronic disease characterized by the development of erythematous, indurated, scaly, pruritic plaques on the skin with cycles of…”
Get full text

Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials by Armstrong, A, Langley, RG, Gordon, KB, Warren, RB, Thaçi, D, Stein Gold, L, Peterson, L, Madden, C, Nunez Gomez, N, De Cuyper, D, Costanzo, A

Get full text

605 Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion by Gold, L. F. Stein, Lebwohl, M.G., Bhatia, N., Lin, T., Pillai, R.

Get full text

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study by Hanifin, Jon M., MD, Ellis, Charles N., MD, Frieden, Ilona J., MD, Fölster-Holst, Regina, MD, Stein Gold, Linda F., MD, Secci, Angelo, MD, Smith, Angela J., PA, Zhao, Cathy, PhD, Kornyeyeva, Elena, MD, PhD, Eichenfield, Lawrence F., MD

“…Background Peripheral leukocytes in patients with atopic dermatitis (AD) have elevated phosphodiesterase-4 activity, which is associated with production of…”
Get full text

Safety and efficacy of tazarotene foam for the treatment of acne vulgaris by Epstein, Erica L, Stein Gold, Linda

“…Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. To review the safety and efficacy studies of tazarotene foam in…”
Get full text